JP2016518124A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016518124A5 JP2016518124A5 JP2016509033A JP2016509033A JP2016518124A5 JP 2016518124 A5 JP2016518124 A5 JP 2016518124A5 JP 2016509033 A JP2016509033 A JP 2016509033A JP 2016509033 A JP2016509033 A JP 2016509033A JP 2016518124 A5 JP2016518124 A5 JP 2016518124A5
- Authority
- JP
- Japan
- Prior art keywords
- mir
- tumor
- patient
- dose
- biological sample
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 206010028980 Neoplasm Diseases 0.000 claims description 111
- 239000002246 antineoplastic agent Substances 0.000 claims description 78
- 239000000090 biomarker Substances 0.000 claims description 74
- 239000012472 biological sample Substances 0.000 claims description 48
- 229940041181 antineoplastic drug Drugs 0.000 claims description 39
- 239000003550 marker Substances 0.000 claims description 34
- 108091070501 miRNA Proteins 0.000 claims description 32
- 108091051828 miR-122 stem-loop Proteins 0.000 claims description 31
- 108091062762 miR-21 stem-loop Proteins 0.000 claims description 31
- 108091053417 miR-885 stem-loop Proteins 0.000 claims description 31
- 108091066112 miR-122-1 stem-loop Proteins 0.000 claims description 30
- 108091057488 miR-122-2 stem-loop Proteins 0.000 claims description 30
- -1 respectively Proteins 0.000 claims description 24
- 108091053561 miR-101-1 stem-loop Proteins 0.000 claims description 22
- 108091088515 miR-197 stem-loop Proteins 0.000 claims description 22
- 108091057431 miR-30d stem-loop Proteins 0.000 claims description 22
- 108091090925 miR-30d-1 stem-loop Proteins 0.000 claims description 22
- 108091059135 miR-429 stem-loop Proteins 0.000 claims description 22
- 108091080309 miR-483 stem-loop Proteins 0.000 claims description 22
- 108091048782 miR-501 stem-loop Proteins 0.000 claims description 22
- 108091057331 miR-509 stem-loop Proteins 0.000 claims description 22
- 108091091880 miR-509-1 stem-loop Proteins 0.000 claims description 22
- 108091051359 miR-509-2 stem-loop Proteins 0.000 claims description 22
- 108091038238 miR-509-3 stem-loop Proteins 0.000 claims description 22
- 108091072761 miR-598 stem-loop Proteins 0.000 claims description 22
- 108091089534 miR-708 stem-loop Proteins 0.000 claims description 22
- 206010009944 Colon cancer Diseases 0.000 claims description 21
- 208000029742 colonic neoplasm Diseases 0.000 claims description 21
- 108091057662 miR-1972-1 stem-loop Proteins 0.000 claims description 21
- 108091063863 miR-1972-2 stem-loop Proteins 0.000 claims description 21
- 108091063796 miR-206 stem-loop Proteins 0.000 claims description 21
- 239000000203 mixture Substances 0.000 claims description 15
- 229940034982 antineoplastic agent Drugs 0.000 claims description 13
- 230000007423 decrease Effects 0.000 claims description 9
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims description 4
- 210000004369 blood Anatomy 0.000 claims description 4
- 239000008280 blood Substances 0.000 claims description 4
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims description 4
- 229960004316 cisplatin Drugs 0.000 claims description 4
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 4
- 229960003668 docetaxel Drugs 0.000 claims description 4
- 239000012530 fluid Substances 0.000 claims description 4
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims description 4
- 229960004768 irinotecan Drugs 0.000 claims description 4
- 210000004880 lymph fluid Anatomy 0.000 claims description 4
- 210000002381 plasma Anatomy 0.000 claims description 4
- 210000003296 saliva Anatomy 0.000 claims description 4
- 210000002966 serum Anatomy 0.000 claims description 4
- 210000001179 synovial fluid Anatomy 0.000 claims description 4
- 230000001225 therapeutic effect Effects 0.000 claims description 4
- 210000002700 urine Anatomy 0.000 claims description 4
- 210000004881 tumor cell Anatomy 0.000 claims description 3
- 241000283984 Rodentia Species 0.000 claims description 2
- 210000000056 organ Anatomy 0.000 claims description 2
- 210000001519 tissue Anatomy 0.000 claims description 2
- 230000004044 response Effects 0.000 claims 4
- 239000003153 chemical reaction reagent Substances 0.000 claims 3
- 230000003247 decreasing effect Effects 0.000 claims 2
- 108091007780 MiR-122 Proteins 0.000 claims 1
- 230000000118 anti-neoplastic effect Effects 0.000 claims 1
- 108091057645 miR-15 stem-loop Proteins 0.000 claims 1
- 230000004043 responsiveness Effects 0.000 claims 1
- 239000002679 microRNA Substances 0.000 description 28
- 201000011510 cancer Diseases 0.000 description 23
- 108091033783 miR-153 stem-loop Proteins 0.000 description 18
- 108091049679 miR-20a stem-loop Proteins 0.000 description 18
- 108091030817 miR-20a-1 stem-loop Proteins 0.000 description 18
- 108091086627 miR-20a-2 stem-loop Proteins 0.000 description 18
- 108091069790 miR-20a-3 stem-loop Proteins 0.000 description 18
- 108091061917 miR-221 stem-loop Proteins 0.000 description 18
- 108091033331 miR-503 stem-loop Proteins 0.000 description 18
- 108091028159 miR-92a-1 stem-loop Proteins 0.000 description 18
- 108091030787 miR-647 stem-loop Proteins 0.000 description 15
- 108091032902 miR-93 stem-loop Proteins 0.000 description 15
- 208000003950 B-cell lymphoma Diseases 0.000 description 10
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 10
- 206010025323 Lymphomas Diseases 0.000 description 10
- 108091007700 MIR543 Proteins 0.000 description 9
- 108091080933 Mir-192/215 microRNA precursor Proteins 0.000 description 9
- 108091063986 let-7f stem-loop Proteins 0.000 description 9
- 108091029710 let-7f-1 stem-loop Proteins 0.000 description 9
- 108091041587 let-7f-2 stem-loop Proteins 0.000 description 9
- 108091064157 miR-106a stem-loop Proteins 0.000 description 9
- 108091041195 miR-106a-1 stem-loop Proteins 0.000 description 9
- 108091051053 miR-106a-2 stem-loop Proteins 0.000 description 9
- 108091045790 miR-106b stem-loop Proteins 0.000 description 9
- 108091035155 miR-10a stem-loop Proteins 0.000 description 9
- 108091084882 miR-10a-1 stem-loop Proteins 0.000 description 9
- 108091025237 miR-1208 stem-loop Proteins 0.000 description 9
- 108091044581 miR-1238 stem-loop Proteins 0.000 description 9
- 108091030503 miR-1260 stem-loop Proteins 0.000 description 9
- 108091046552 miR-1260a stem-loop Proteins 0.000 description 9
- 108091062133 miR-1265 stem-loop Proteins 0.000 description 9
- 108091082516 miR-1267 stem-loop Proteins 0.000 description 9
- 108091091207 miR-127 stem-loop Proteins 0.000 description 9
- 108091047499 miR-1271 stem-loop Proteins 0.000 description 9
- 108091030660 miR-1468 stem-loop Proteins 0.000 description 9
- 108091083308 miR-155 stem-loop Proteins 0.000 description 9
- 108091091301 miR-155-1 stem-loop Proteins 0.000 description 9
- 108091041686 miR-155-2 stem-loop Proteins 0.000 description 9
- 108091031326 miR-15b stem-loop Proteins 0.000 description 9
- 108091027943 miR-16 stem-loop Proteins 0.000 description 9
- 108091074057 miR-16-1 stem-loop Proteins 0.000 description 9
- 108091056204 miR-16-2 stem-loop Proteins 0.000 description 9
- 108091092591 miR-181a-2 stem-loop Proteins 0.000 description 9
- 108091074194 miR-181b-1 stem-loop Proteins 0.000 description 9
- 108091038599 miR-181b-2 stem-loop Proteins 0.000 description 9
- 108091061809 miR-181b-3 stem-loop Proteins 0.000 description 9
- 108091081505 miR-190 stem-loop Proteins 0.000 description 9
- 108091086834 miR-190-2 stem-loop Proteins 0.000 description 9
- 108091065212 miR-190b stem-loop Proteins 0.000 description 9
- 108091086416 miR-192 stem-loop Proteins 0.000 description 9
- 108091037787 miR-19b stem-loop Proteins 0.000 description 9
- 108091028067 miR-19b-1 stem-loop Proteins 0.000 description 9
- 108091091434 miR-19b-2 stem-loop Proteins 0.000 description 9
- 108091045665 miR-202 stem-loop Proteins 0.000 description 9
- 108091039792 miR-20b stem-loop Proteins 0.000 description 9
- 108091055878 miR-20b-1 stem-loop Proteins 0.000 description 9
- 108091027746 miR-20b-2 stem-loop Proteins 0.000 description 9
- 108091088730 miR-215 stem-loop Proteins 0.000 description 9
- 108091035591 miR-23a stem-loop Proteins 0.000 description 9
- 108091092825 miR-24 stem-loop Proteins 0.000 description 9
- 108091048857 miR-24-1 stem-loop Proteins 0.000 description 9
- 108091047483 miR-24-2 stem-loop Proteins 0.000 description 9
- 108091060033 miR-298 stem-loop Proteins 0.000 description 9
- 108091050195 miR-302b stem-loop Proteins 0.000 description 9
- 108091082689 miR-302b-1 stem-loop Proteins 0.000 description 9
- 108091089412 miR-302b-2 stem-loop Proteins 0.000 description 9
- 108091043187 miR-30a stem-loop Proteins 0.000 description 9
- 108091029750 miR-30a-1 stem-loop Proteins 0.000 description 9
- 108091030035 miR-30a-2 stem-loop Proteins 0.000 description 9
- 108091063344 miR-30b stem-loop Proteins 0.000 description 9
- 108091089005 miR-329 stem-loop Proteins 0.000 description 9
- 108091090692 miR-337 stem-loop Proteins 0.000 description 9
- 108091068963 miR-361 stem-loop Proteins 0.000 description 9
- 108091062637 miR-367 stem-loop Proteins 0.000 description 9
- 108091036633 miR-370 stem-loop Proteins 0.000 description 9
- 108091043953 miR-373 stem-loop Proteins 0.000 description 9
- 108091087125 miR-376a stem-loop Proteins 0.000 description 9
- 108091073138 miR-376a-3 stem-loop Proteins 0.000 description 9
- 108091024291 miR-378 stem-loop Proteins 0.000 description 9
- 108091025661 miR-378a stem-loop Proteins 0.000 description 9
- 108091050135 miR-382 stem-loop Proteins 0.000 description 9
- 108091030938 miR-424 stem-loop Proteins 0.000 description 9
- 108091081444 miR-503-1 stem-loop Proteins 0.000 description 9
- 108091023262 miR-503-2 stem-loop Proteins 0.000 description 9
- 108091053329 miR-510 stem-loop Proteins 0.000 description 9
- 108091057485 miR-515-1 stem-loop Proteins 0.000 description 9
- 108091029052 miR-515-2 stem-loop Proteins 0.000 description 9
- 108091024525 miR-515-3 stem-loop Proteins 0.000 description 9
- 108091040524 miR-518a-1 stem-loop Proteins 0.000 description 9
- 108091028747 miR-518a-2 stem-loop Proteins 0.000 description 9
- 108091045883 miR-518a-3 stem-loop Proteins 0.000 description 9
- 108091050322 miR-518a-4 stem-loop Proteins 0.000 description 9
- 108091035240 miR-518c stem-loop Proteins 0.000 description 9
- 108091044445 miR-518f stem-loop Proteins 0.000 description 9
- 108091036604 miR-518f-1 stem-loop Proteins 0.000 description 9
- 108091080798 miR-518f-2 stem-loop Proteins 0.000 description 9
- 108091029517 miR-520h stem-loop Proteins 0.000 description 9
- 108091063385 miR-526b stem-loop Proteins 0.000 description 9
- 108091076271 miR-543 stem-loop Proteins 0.000 description 9
- 108091037006 miR-548h-1 stem-loop Proteins 0.000 description 9
- 108091028705 miR-548h-2 stem-loop Proteins 0.000 description 9
- 108091024683 miR-548h-3 stem-loop Proteins 0.000 description 9
- 108091041881 miR-548h-4 stem-loop Proteins 0.000 description 9
- 108091050095 miR-548h-5 stem-loop Proteins 0.000 description 9
- 108091030944 miR-588 stem-loop Proteins 0.000 description 9
- 108091028939 miR-621 stem-loop Proteins 0.000 description 9
- 108091041759 miR-622 stem-loop Proteins 0.000 description 9
- 108091066725 miR-623 stem-loop Proteins 0.000 description 9
- 108091049896 miR-629 stem-loop Proteins 0.000 description 9
- 108091092836 miR-887 stem-loop Proteins 0.000 description 9
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 8
- 206010060862 Prostate cancer Diseases 0.000 description 8
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 8
- 201000005202 lung cancer Diseases 0.000 description 8
- 208000020816 lung neoplasm Diseases 0.000 description 8
- 108091079021 miR-27a stem-loop Proteins 0.000 description 8
- 108091043371 miR-27a-1 stem-loop Proteins 0.000 description 8
- 108091029509 miR-802 stem-loop Proteins 0.000 description 8
- 108091023402 miR-26a-2 stem-loop Proteins 0.000 description 7
- 108091024127 miR-634 stem-loop Proteins 0.000 description 7
- 108091026807 MiR-214 Proteins 0.000 description 5
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 4
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 description 4
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 4
- 230000003325 follicular Effects 0.000 description 4
- 201000003444 follicular lymphoma Diseases 0.000 description 4
- 108091026331 miR-214 stem-loop Proteins 0.000 description 4
- 108091048888 miR-214-1 stem-loop Proteins 0.000 description 4
- 108091078347 miR-214-2 stem-loop Proteins 0.000 description 4
- 108091035552 miR-214-3 stem-loop Proteins 0.000 description 4
- 208000002008 AIDS-Related Lymphoma Diseases 0.000 description 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 2
- 208000036170 B-Cell Marginal Zone Lymphoma Diseases 0.000 description 2
- 206010005003 Bladder cancer Diseases 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 206010008342 Cervix carcinoma Diseases 0.000 description 2
- 208000017604 Hodgkin disease Diseases 0.000 description 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 2
- 206010053574 Immunoblastic lymphoma Diseases 0.000 description 2
- 208000028018 Lymphocytic leukaemia Diseases 0.000 description 2
- 206010025312 Lymphoma AIDS related Diseases 0.000 description 2
- 201000003791 MALT lymphoma Diseases 0.000 description 2
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 description 2
- 208000034578 Multiple myelomas Diseases 0.000 description 2
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 description 2
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 2
- 206010033128 Ovarian cancer Diseases 0.000 description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 description 2
- 206010033701 Papillary thyroid cancer Diseases 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 208000007452 Plasmacytoma Diseases 0.000 description 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 2
- 208000011767 Sarcoma of cervix uteri Diseases 0.000 description 2
- 208000000453 Skin Neoplasms Diseases 0.000 description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 2
- 208000016025 Waldenstroem macroglobulinemia Diseases 0.000 description 2
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 201000010881 cervical cancer Diseases 0.000 description 2
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 2
- 206010017758 gastric cancer Diseases 0.000 description 2
- 201000009277 hairy cell leukemia Diseases 0.000 description 2
- 208000025750 heavy chain disease Diseases 0.000 description 2
- 208000021173 high grade B-cell lymphoma Diseases 0.000 description 2
- 210000003292 kidney cell Anatomy 0.000 description 2
- 201000007270 liver cancer Diseases 0.000 description 2
- 208000014018 liver neoplasm Diseases 0.000 description 2
- 208000003747 lymphoid leukemia Diseases 0.000 description 2
- 201000007924 marginal zone B-cell lymphoma Diseases 0.000 description 2
- 208000021937 marginal zone lymphoma Diseases 0.000 description 2
- 108091065445 miR-6-4 stem-loop Proteins 0.000 description 2
- 210000004180 plasmocyte Anatomy 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 201000000849 skin cancer Diseases 0.000 description 2
- 206010041823 squamous cell carcinoma Diseases 0.000 description 2
- 201000011549 stomach cancer Diseases 0.000 description 2
- 208000030045 thyroid gland papillary carcinoma Diseases 0.000 description 2
- 201000005112 urinary bladder cancer Diseases 0.000 description 2
- 108091059916 miR-7a stem-loop Proteins 0.000 description 1
- 108091057491 miR-7a-1 stem-loop Proteins 0.000 description 1
- 108091064316 miR-7a-2 stem-loop Proteins 0.000 description 1
- 108091050178 miR-7a-6 stem-loop Proteins 0.000 description 1
- 108091055585 miR-7a-7 stem-loop Proteins 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361812033P | 2013-04-15 | 2013-04-15 | |
| US61/812,033 | 2013-04-15 | ||
| PCT/US2014/034217 WO2014172376A2 (en) | 2013-04-15 | 2014-04-15 | Markers of tumor cell response to anti-cancer therapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016518124A JP2016518124A (ja) | 2016-06-23 |
| JP2016518124A5 true JP2016518124A5 (enExample) | 2017-06-01 |
Family
ID=51686961
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016509033A Ceased JP2016518124A (ja) | 2013-04-15 | 2014-04-15 | 抗がん療法に対する腫瘍細胞応答マーカー |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US10023916B2 (enExample) |
| EP (1) | EP2986739B1 (enExample) |
| JP (1) | JP2016518124A (enExample) |
| KR (1) | KR20150140728A (enExample) |
| CN (1) | CN105308189B (enExample) |
| AU (1) | AU2014254091B2 (enExample) |
| BR (1) | BR112015026095A8 (enExample) |
| CA (1) | CA2909642A1 (enExample) |
| MX (1) | MX2015014486A (enExample) |
| MY (1) | MY180365A (enExample) |
| RU (1) | RU2664180C2 (enExample) |
| SG (2) | SG11201508058TA (enExample) |
| WO (1) | WO2014172376A2 (enExample) |
| ZA (1) | ZA201507309B (enExample) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9510569B2 (en) | 2013-03-13 | 2016-12-06 | Regeneron Pharmaceuticals, Inc. | Genetically modified mouse with an inducible Acvr1 gene with a mutant R206H exon 5 that has ectopic bone formation |
| US10023916B2 (en) | 2013-04-15 | 2018-07-17 | Regeneron Pharmaceuticals, Inc. | Markers of tumor cell response to anti-cancer therapy |
| CN104388561A (zh) * | 2014-11-14 | 2015-03-04 | 浙江理工大学 | 肝癌生物标记物及其用途 |
| CN106636315B (zh) * | 2015-10-30 | 2020-06-02 | 益善生物技术股份有限公司 | 淋巴瘤相关microRNA检测试剂盒 |
| CN106636311B (zh) * | 2015-10-30 | 2020-06-02 | 益善生物技术股份有限公司 | 大肠癌相关microRNA检测试剂盒 |
| WO2017207623A1 (en) * | 2016-05-31 | 2017-12-07 | Université de Lausanne | Mirna as biomarkers and regulators of cancer stem cells |
| CN105950768A (zh) * | 2016-07-01 | 2016-09-21 | 江苏医诺万细胞诊疗有限公司 | 一种microRNA组合作为肿瘤标志物辅助诊断多种肿瘤的试剂盒及其检测方法 |
| CN106350582B (zh) * | 2016-08-25 | 2020-02-14 | 朱伟 | 一种与肺鳞癌辅助诊断相关的血清miRNA标志物及其应用 |
| CN106282360B (zh) * | 2016-08-31 | 2019-11-08 | 武汉博杰生物医学科技有限公司 | 一种用于结肠癌预测转移的血浆miRNA组合、其探针组合物及应用 |
| CN107913284B (zh) * | 2016-10-09 | 2022-09-16 | 上海市东方医院 | miRNA302-367簇的微小RNA在靶向抑制血管新生和肿瘤生长的应用 |
| CN106778073B (zh) * | 2017-01-19 | 2019-09-06 | 北京吉因加科技有限公司 | 一种评估肿瘤负荷变化的方法和系统 |
| CN106834470A (zh) * | 2017-02-17 | 2017-06-13 | 张灏 | miRNA在制备癌症诊断试剂盒中的用途 |
| CN106676196B (zh) * | 2017-03-10 | 2019-05-07 | 上海核盾生物科技有限公司 | 一种用于诊断重度吸烟人群中肺鳞癌患者的非侵入性标记物及试剂盒 |
| CN107326092B (zh) * | 2017-08-25 | 2021-07-20 | 深圳市恩普电子技术有限公司 | 大肠癌相关的miRNA作为生物标志物的应用及大肠癌检测试剂盒 |
| CN107858427B (zh) * | 2017-10-24 | 2021-03-02 | 昆明理工大学 | miR-429在制备乳腺癌诊断和检测试剂盒中的应用 |
| CN108220381A (zh) * | 2017-12-07 | 2018-06-29 | 国家卫生计生委科学技术研究所 | 试剂在制备药物中的用途以及筛选药物的方法 |
| CN108531586B (zh) * | 2018-03-19 | 2022-03-29 | 朱伟 | 一种与乳腺癌辅助诊断相关的位于X染色体上的循环miRNA标志物及其应用 |
| CN109097473A (zh) * | 2018-08-24 | 2018-12-28 | 南京求臻基因科技有限公司 | 一种非小细胞肺癌辅助诊断试剂盒 |
| KR102256747B1 (ko) * | 2018-10-30 | 2021-05-25 | 가톨릭대학교 산학협력단 | 엑소좀 miR-125b를 포함하는 간암 전이 진단 또는 예측용 바이오마커 및 이의 용도 |
| US12257340B2 (en) | 2018-12-03 | 2025-03-25 | Agensys, Inc. | Pharmaceutical compositions comprising anti-191P4D12 antibody drug conjugates and methods of use thereof |
| CN109593852B (zh) * | 2018-12-24 | 2022-03-08 | 朱伟 | 一种与鼻咽癌辅助诊断相关的血清miRNA标志物及其应用 |
| EP3969053A4 (en) * | 2019-05-15 | 2023-01-11 | The University of Chicago | LACTATE RESPONSE SYSTEM AND METHODS |
| CN110484620B (zh) * | 2019-08-09 | 2023-09-19 | 深圳市第二人民医院 | 生物标志物及其在制备诊断ptmc的产品中的应用 |
| WO2021108043A1 (en) | 2019-11-27 | 2021-06-03 | University Of Cincinnati | Assessing treatment response with estimated number of tumor cells |
| KR102293777B1 (ko) * | 2019-12-31 | 2021-08-25 | 연세대학교 산학협력단 | 신규한 UQCRB-관련 순환 miRNA 바이오 마커 및 이를 이용한 대장암의 진단 방법 |
| WO2021142088A1 (en) * | 2020-01-07 | 2021-07-15 | The Trustees Of The University Of Pennsylvania | Source specific exosomes for determining avoidance of cancer treatment and avoidance of checkpoint inhibitor therapies |
| CN113930505B (zh) * | 2020-03-30 | 2022-04-19 | 中国医学科学院肿瘤医院 | 用于肺癌诊断的试剂盒及装置 |
| CN111808950B (zh) * | 2020-06-02 | 2023-11-14 | 中南大学湘雅医院 | 一种甲状腺乳头状癌miRNA标志物及其应用 |
| CA3185666A1 (en) * | 2020-06-19 | 2021-12-23 | Agensys, Inc. | Markers for use in methods for treating cancers with antibody drug conjugates (adc) |
| CN111676291B (zh) * | 2020-07-14 | 2021-04-13 | 徐州医科大学 | 一种用于肺癌患病风险评估的miRNA标志物 |
| CN113025713B (zh) * | 2021-02-23 | 2022-11-22 | 浙江东睿生物科技有限公司 | 用于预测肿瘤患者对特定抗肿瘤药物的敏感性的生物标志物的应用 |
| CN114150063B (zh) * | 2021-12-09 | 2024-12-17 | 觅瑞（杭州）生物科技有限公司 | 膀胱癌诊断用尿液miRNA标志物、诊断试剂及试剂盒 |
| CN115029347B (zh) * | 2022-05-11 | 2024-02-20 | 珠海中科先进技术研究院有限公司 | 识别和调控肝肾细胞纤维化的分子监测序列、重组质粒、抑制病毒 |
| WO2024006581A1 (en) * | 2022-07-01 | 2024-01-04 | City Of Hope | Biomarkers in colorectal cancer |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2548394A1 (en) * | 2003-12-12 | 2005-06-30 | Bayer Pharmaceuticals Corporation | Methods for prediction and prognosis of cancer, and monitoring cancer therapy |
| JP5039544B2 (ja) * | 2004-06-18 | 2012-10-03 | ジェネンテック， インコーポレイテッド | 腫瘍の治療 |
| ES2343204T3 (es) | 2005-09-20 | 2010-07-26 | Scinopharm Singapore Pte, Ltd. | Formas cristalinas nuevas de hidrocloruro de irinotecan. |
| ES2442890T3 (es) | 2006-07-13 | 2014-02-14 | The Ohio State University Research Foundation | Métodos y composiciones basados en micro-ARN para el diagnóstico y el tratamiento de enfermedades relacionadas con el colon |
| US20100004253A1 (en) * | 2006-09-19 | 2010-01-07 | Novartis Ag | Biomarkers of target modulation, efficacy, diagnosis and/or prognosis for raf inhibitors |
| WO2008143795A1 (en) | 2007-05-11 | 2008-11-27 | Champions Biotechnology, Inc. | Human mesenchymal chrondrosarcoma xenograft model and its use in chemosensitivity testing |
| ES2600165T3 (es) * | 2008-02-28 | 2017-02-07 | The Ohio State University Research Foundation | Antagonistas de miR-32 para aumentar la respuesta del cáncer de próstata a la apoptosis |
| EP2334805A1 (en) * | 2008-06-04 | 2011-06-22 | Andor Pivarcsi | Skin cancer associated micrornas |
| JP2012509675A (ja) | 2008-11-25 | 2012-04-26 | ジェン−プロウブ インコーポレイテッド | 低分子ｒｎａを検出するための組成物および方法、ならびにその使用 |
| US20120231970A1 (en) | 2009-09-30 | 2012-09-13 | Japan Health Sciences Foundation | Colon cancer marker and method for testing for colon cancer |
| WO2011156777A1 (en) | 2010-06-10 | 2011-12-15 | Fred Hutchinson Cancer Research Center | Use of blood mir-210 for cancer prognosis |
| US20120264131A1 (en) | 2011-03-18 | 2012-10-18 | Baylor Research Institute | CHANGES IN THE EXPRESSION OF miR-200c/141 CLUSTER OF microRNAs AS BIOMARKERS FOR EPITHELIAL-TO-MESENCHYMAL TRANSITION IN HUMAN COLORECTAL CANCER METASTASIS |
| WO2012170711A1 (en) | 2011-06-07 | 2012-12-13 | Caris Life Sciences Luxembourg Holdings, S.A.R.L | Circulating biomarkers for cancer |
| WO2012174293A2 (en) | 2011-06-14 | 2012-12-20 | Nestec Sa | Methods for identifying inflammatory bowel disease patients with dysplasia or cancer |
| WO2014078850A1 (en) * | 2012-11-19 | 2014-05-22 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Method of cancer diagnosis, progression and response to therapy using a primary xenograft mouse model for cancer serum biomarker discovery |
| US10023916B2 (en) | 2013-04-15 | 2018-07-17 | Regeneron Pharmaceuticals, Inc. | Markers of tumor cell response to anti-cancer therapy |
-
2014
- 2014-04-15 US US14/253,592 patent/US10023916B2/en not_active Expired - Fee Related
- 2014-04-15 JP JP2016509033A patent/JP2016518124A/ja not_active Ceased
- 2014-04-15 SG SG11201508058TA patent/SG11201508058TA/en unknown
- 2014-04-15 MY MYPI2015703672A patent/MY180365A/en unknown
- 2014-04-15 SG SG10201708464TA patent/SG10201708464TA/en unknown
- 2014-04-15 WO PCT/US2014/034217 patent/WO2014172376A2/en not_active Ceased
- 2014-04-15 KR KR1020157031485A patent/KR20150140728A/ko not_active Ceased
- 2014-04-15 EP EP14784689.3A patent/EP2986739B1/en not_active Not-in-force
- 2014-04-15 BR BR112015026095A patent/BR112015026095A8/pt not_active Application Discontinuation
- 2014-04-15 MX MX2015014486A patent/MX2015014486A/es unknown
- 2014-04-15 RU RU2015148638A patent/RU2664180C2/ru not_active IP Right Cessation
- 2014-04-15 CA CA2909642A patent/CA2909642A1/en not_active Abandoned
- 2014-04-15 AU AU2014254091A patent/AU2014254091B2/en not_active Expired - Fee Related
- 2014-04-15 CN CN201480032378.8A patent/CN105308189B/zh not_active Expired - Fee Related
-
2015
- 2015-10-01 ZA ZA2015/07309A patent/ZA201507309B/en unknown
-
2018
- 2018-06-12 US US16/006,641 patent/US20180291468A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016518124A5 (enExample) | ||
| Singh et al. | TNBC: potential targeting of multiple receptors for a therapeutic breakthrough, nanomedicine, and immunotherapy | |
| RU2015148638A (ru) | Маркеры ответа опухолевых клеток на противораковую терапию | |
| Pan et al. | Genome-Scale CRISPR screen identifies LAPTM5 driving lenvatinib resistance in hepatocellular carcinoma | |
| Nedeljković et al. | Mechanisms of chemotherapy resistance in triple-negative breast cancer—how we can rise to the challenge | |
| Hamamoto et al. | Identification of microRNAs differentially expressed between lung squamous cell carcinoma and lung adenocarcinoma | |
| Indini et al. | Targeting KRAS in solid tumors: current challenges and future opportunities of novel KRAS inhibitors | |
| Huang et al. | PBK/TOPK: An effective drug target with diverse therapeutic potential | |
| Dong et al. | Meloxicam executes its antitumor effects against hepatocellular carcinoma in COX-2-dependent and-independent pathways | |
| Singh et al. | Overcoming acquired drug resistance to cancer therapies through targeted STAT3 inhibition | |
| Eoh et al. | MicroRNA-630 inhibitor sensitizes chemoresistant ovarian cancer to chemotherapy by enhancing apoptosis | |
| CN107923918A (zh) | 用于开发个性化药物治疗计划和基于蛋白质组谱的靶向药物开发的方法 | |
| Liu et al. | Mouse avatar models of esophageal squamous cell carcinoma proved the potential for EGFR-TKI afatinib and uncovered Src family kinases involved in acquired resistance | |
| Jin et al. | Differential response to EGFR-and VEGF-targeted therapies in patient-derived tumor tissue xenograft models of colon carcinoma and related metastases | |
| Imai et al. | Individual-level data on the relationships of progression-free survival, post-progression survival, and tumor response with overall survival in patients with advanced non-squamous non-small cell lung cancer | |
| Li et al. | Immunoregulatory mechanism studies of ginseng leaves on lung cancer based on network pharmacology and molecular docking | |
| Schlick et al. | Recent advances in pancreatic cancer: novel prognostic biomarkers and targeted therapy—a review of the literature | |
| Caserta et al. | Gender differences and miRNAs expression in cancer: implications on prognosis and susceptibility | |
| Singh et al. | Breast cancer: miRNAs monitoring chemoresistance and systemic therapy | |
| Kim et al. | Cancer cell‑specific anticancer effects of Coptis chinensis on gefitinib‑resistant lung cancer cells are mediated through the suppression of Mcl‑1 and Bcl‑2 | |
| Shen et al. | Pien Tze Huang inhibits the proliferation of human colon carcinoma cells by arresting G1/S cell cycle progression | |
| Jung et al. | Pilot study of sirolimus in patients with PIK3CA mutant/amplified refractory solid cancer | |
| Bissinger et al. | EGFR and Cortactin: Markers for potential double target therapy in oral squamous cell carcinoma | |
| Chen et al. | The use of chemical-chemical interaction and chemical structure to identify new candidate chemicals related to lung cancer | |
| Xu et al. | Overexpression of miR-206 in osteosarcoma and its associated molecular mechanisms as assessed through TCGA and GEO databases |